Stage IV

Questions discussed in this category

When do you consider HER2-targeting antibody drug conjugates in the first line setting for metastatic HER2 positive, ER negative breast cancer?

Given strong TDXd efficacy in these patients is there a role to use it earlier than 2nd line? How does prior Her2-directed and/or taxane therapy...

5 Answers available

Would you deliver SBRT to the adrenal gland if a patient has already undergone contralateral adrenalectomy for oligometastatic NSCLC?

What would you anticipate with regard to potential adrenal toxicity when the patient has only 1 functioning adrenal gland? There are no other sites of...

3 Answers available

What is the rate of a cardiac events that you quote to a patient with preexisting heart disease going on trastuzumab for metastatic Her2+ breast cancer?

How does it vary for patients with a history of hypertension, diabetes, CHF, and coronary artery disease?

1 Answer available

How do you minimize the risk of cardiotoxicity in metastatic Her2 + breast cancer patients who are receiving trastuzumab and have a history of pre-existing cardiac disease?

1 Answer available

What is your preferred regimen for triple positive breast cancer with visceral metastasis while on adjuvant AI?

Would you consider using CKD inhibitors upfront in triple positive breast cancer previously treated with chemotherapy, endocrine therapy, and Hercepti...

2 Answers available

What is your preferred regimen for triple positive breast cancer with bone only recurrence?

Would you consider using ckd inhibitors in triple positive breast cancer previously treated with chemotherapy, endocrine therapy, and Herceptin? NCCN ...

1 Answer available

Will you continue anti-estrogen therapy in the setting of initiation of TDM-1 for patients with metastatic ER+/HER2+ breast cancer?

1 Answer available

For women with metastatic HER2 + breast cancer who achieve a complete response, how long do you continue on HER2-directed therapies?

Do you ever consider de-escalating or stopping therapy in this situation? What is your approach to this conversation?

3 Answers available

Is there a role for any of the CDK4/6 inhibitors in ER+/HER2+ or ER-/HER2+ metastatic breast cancer?

1 Answer available

Papers discussed in this category

Breast cancer research : BCR, 2009

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.

Cancer cell, 2012-10-16

The requirement for cyclin D function in tumor maintenance.

Cancer cell, 2016-03-14

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.

Cancer discovery, 2016-07

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.

Cancer, 2015-12-15

Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy.

Lancet (London, England), 2009-12-19

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.

The Lancet. Oncology, 2014-06

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

The New England journal of medicine, 2012-11-08

Trastuzumab emtansine for HER2-positive advanced breast cancer.

J. Clin. Oncol.,

A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia.

The New England journal of medicine, 2012-01-12

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-10-10

T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab.

N Engl J Med,

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.

N Engl J Med, 2019 Dec 11

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.

The New England journal of medicine, 2015-02-19

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

Cochrane Database Syst Rev, 2008 Apr 16

Cardioprotective interventions for cancer patients receiving anthracyclines.

Eur. J. Cancer, 2013 May 22

Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-09-01

Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.

Related Topics